IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jake burns who wrote (498)	6/12/1998 9:05:00 AM
From: Emec	Read Replies (2) of 1510

fROM briefing.com 08:53 ET Immune Response Corp (IMNR) 13 11/16: Company and Agouron Pharmaceuticals (AGPH) announced that they have agreed to collaborate on the final development and commercialization of REMUNE, a therapy for the treatment of HIV. The drug currently in a Phase III clinical endpoint trial. Immune Response may receive as much as $77 million over next 2years, including license and milestone payments of $45 million, payments to support development of $18 million and the purchase of $14 million of Immune Response common stock priced at premium to market. Stock indicated 1 3/8 higher.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next